Medicines New Zealand Unveils 2022 Transfer of Value Reports to Enhance Transparency

By Staff Writer

August 30, 2023

Medicines New Zealand is delighted to announce the launch of the 2022 Transfer of Value reports. These reports, representing the organisation’s second annual publication, offer a transparent snapshot of the financial interactions between biopharmaceutical companies and healthcare professionals. This initiative underscores our unwavering commitment to transparency and ethical standards within the industry.

Dr Graeme Jarvis, CEO of Medicines New Zealand, remarked on the release, “This information is what the joint project between industry and healthcare practitioners was designed to deliver.”

The reports aim to shed light on the financial relationships and interactions between biopharmaceutical companies and healthcare professionals. They seek to bolster transparency and uphold ethical standards within the industry.

“Public reporting of payments made by the biopharmaceutical industry to healthcare professionals is the right thing to do from a transparency perspective,” said Dr Jarvis. “This commitment allows patients and the public to gain insight into the nature of these interactions and have confidence in the ethical standards and patient-centric approach of healthcare professionals in New Zealand.”

The 2022 Transfer of Value reports provide a comprehensive overview of the financial interactions between Medicines New Zealand member companies and healthcare professionals. These interactions include sponsorships for healthcare providers to attend medical education events and conferences, which ultimately benefit patient care and contribute to the continuous improvement of healthcare practices.

Medicines New Zealand invites all interested parties to access the Transfer of Value reports from its member companies. The reports serve as a valuable resource for those seeking a deeper understanding of the financial relationships that drive advancements in patient care.

Reference url

Recent Posts

drug price transparency
     

Impending Net Drug Price Transparency Regulation in the U.S.

💡 Are you ready for a potential game-changer in drug pricing transparency?

CMS Administrator Mehmet Oz has hinted at a new rule aimed at enforcing stricter disclosures for drug prices, requiring healthcare companies to reveal actual transaction costs. This could reshape how price transparency is managed across the industry and challenge pharmacy benefit managers to rethink rebate practices.

Curious about how this will impact healthcare economics and what it means for drug affordability? Dive into the article for all the insights!

#SyenzaNews #healthcare #HealthEconomics

Sword Health mental health
         

How Does Mind’s AI-Driven Mental Healthcare Transform Care?

🤔 Are we ready to embrace AI in mental health care?

Sword Health has just secured €34.6 million to launch **Mind**, an innovative AI-powered mental health solution, blending licensed clinicians with continuous monitoring through wearables. This strategic expansion aims to address the pressing global mental health crisis while promoting personalized and proactive care models. 🌍🧠

Dive into how Sword Health is revolutionizing healthcare and bridging the gap between technology and clinical expertise.

#SyenzaNews #HealthTech #AIinHealthcare #DigitalTransformation

transparency in industry partnerships
   

Transparency in Industry Partnerships: Building Trust

🔍 How does transparency in industry partnerships impact patient care?

In the evolving landscape of healthcare, EFPIA’s mandatory disclosure requirements for financial interactions underscore the vital role of transparency in fostering trust and collaboration. By detailing financial transfers to healthcare professionals and organizations, the European Disclosure Gateway facilitates informed decision-making and strengthens relationships between stakeholders.

Have a look at the article to explore how these initiatives not only enhance public confidence but also drive innovation in treatments!

#SyenzaNews #HealthcareInnovation #HealthEconomics #innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.